Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I am continuing to add here...
PETZ oversold at these levels. I started acc a position today
I Started acc a position today! Oversold here, good for a bounce...
OVERSOLD at these levels..I am loading up BIG today!
OVERSOLD at these levels. I am LOADING BIG before the market close today!
I really appreciate your posts on company news Thanks..added you
GTCH OVERSOLD .62 last high 1.79..news today..GBT Files Continuation For Its Communication Microchip Patent
SAN DIEGO, Dec. 31, 2019 (GLOBE NEWSWIRE) -- GBT Technologies Inc.(GTCH) ("GBT”, or the “Company”), a company specializing in the development of Internet of Things (IoT) and Artificial Intelligence (AI) enabled networking and tracking technologies, including its GopherInsight™ wireless mesh network technology platform and its Avant! AI, for both mobile and fixed solutions, announced that the Company filed on December 27, 2019 a continuation application for its communication microchip patent for its GopherInsight™, in order to further protect its innovative concepts and methods. The application has been assigned serial number 16727983. The patent is expected to be granted during the first quarter of 2020.
GBT's GopherInsight™ microchip seeks to protect innovative integrated circuit technology that is targeted for IoT/mobile devices. GopherInsight™ works through its own private, secured network to transfer and share information, and is self-adapting to a device's usage patterns; the system is usage-aware and modulates its operation mode according to the device's power option, data transfer, security and network's capabilities. The chip communicates via satellite and/or its private network in order to connect with other same chips that are on the network. The chip is operating in real time, enabling GBT’s advanced security and auto error-correction communication protocol.
The comprehensive patent seeks to cover new concepts and methodologies within the communication domain, among them mobile parallel processing, network database management, radio-based private, secured communication network, airplane mode and more.
"We are especially proud of this innovative IP and that's why we will pursue maximum protection for this invention," stated Danny Rittman, GBT’s CTO. "We believe that the patent covers ground-breaking concepts in the communications and IoT field. We are excited that it is scheduled to be granted during the first quarter of 2020 and that we are moving further to protect the wide variety of technological concepts and methodologies by filing for continuation. In the continuation application we made our best efforts to further protect all claims to the maximum extent in order to implement them in future electronic circuits.
“The microchip is targeted to be implemented as an independent IP unit on an existing chip or on device's micro SIM/Board. We believe this creates an entire whole world of business opportunities licensing it to IC design firms and devices manufactures. The new microchip systems and methods will enable the design of high performance, low power, robust communication microchips that will enhance our daily lives within wide variety of domains. The technology covers advanced node manufacturing to ensure low unit cost and high silicon yield. GBT plans to offer this technology to IC design houses once the patent is granted, and to seek partnerships within the communication IoT industry in order to create new technological advancements."
About GBT Technologies Inc.(GTCH)
GBT Technologies Inc. (GTCH) (“GBT”) (http://gopherprotocol.com/) is a development-stage company which considers itself a native IoT creator, developing Internet of Things (IoT) and Artificial Intelligence (AI) enabled mobile technology platforms. GBT has a portfolio of Intellectual Property that, when commercialized, will include smart microchips, mobile and security applications and protocols, and supporting cloud software. GBT’s system envisions the creation of a global mesh network. The core of the system will be its advanced microchip technology that can be installed in any mobile or fixed device worldwide. GBT envisions this system as a low-cost, secure, private mesh network between any enabled devices, providing shared processing, advanced mobile database management/sharing and enhanced mobile features as an alternative to traditional carrier services.
news..GBT Files Continuation For Its Communication Microchip Patent
SAN DIEGO, Dec. 31, 2019 (GLOBE NEWSWIRE) -- GBT Technologies Inc.(GTCH) ("GBT”, or the “Company”), a company specializing in the development of Internet of Things (IoT) and Artificial Intelligence (AI) enabled networking and tracking technologies, including its GopherInsight™ wireless mesh network technology platform and its Avant! AI, for both mobile and fixed solutions, announced that the Company filed on December 27, 2019 a continuation application for its communication microchip patent for its GopherInsight™, in order to further protect its innovative concepts and methods. The application has been assigned serial number 16727983. The patent is expected to be granted during the first quarter of 2020.
GBT's GopherInsight™ microchip seeks to protect innovative integrated circuit technology that is targeted for IoT/mobile devices. GopherInsight™ works through its own private, secured network to transfer and share information, and is self-adapting to a device's usage patterns; the system is usage-aware and modulates its operation mode according to the device's power option, data transfer, security and network's capabilities. The chip communicates via satellite and/or its private network in order to connect with other same chips that are on the network. The chip is operating in real time, enabling GBT’s advanced security and auto error-correction communication protocol.
The comprehensive patent seeks to cover new concepts and methodologies within the communication domain, among them mobile parallel processing, network database management, radio-based private, secured communication network, airplane mode and more.
"We are especially proud of this innovative IP and that's why we will pursue maximum protection for this invention," stated Danny Rittman, GBT’s CTO. "We believe that the patent covers ground-breaking concepts in the communications and IoT field. We are excited that it is scheduled to be granted during the first quarter of 2020 and that we are moving further to protect the wide variety of technological concepts and methodologies by filing for continuation. In the continuation application we made our best efforts to further protect all claims to the maximum extent in order to implement them in future electronic circuits.
“The microchip is targeted to be implemented as an independent IP unit on an existing chip or on device's micro SIM/Board. We believe this creates an entire whole world of business opportunities licensing it to IC design firms and devices manufactures. The new microchip systems and methods will enable the design of high performance, low power, robust communication microchips that will enhance our daily lives within wide variety of domains. The technology covers advanced node manufacturing to ensure low unit cost and high silicon yield. GBT plans to offer this technology to IC design houses once the patent is granted, and to seek partnerships within the communication IoT industry in order to create new technological advancements."
About GBT Technologies Inc.(GTCH)
GBT Technologies Inc. (GTCH) (“GBT”) (http://gopherprotocol.com/) is a development-stage company which considers itself a native IoT creator, developing Internet of Things (IoT) and Artificial Intelligence (AI) enabled mobile technology platforms. GBT has a portfolio of Intellectual Property that, when commercialized, will include smart microchips, mobile and security applications and protocols, and supporting cloud software. GBT’s system envisions the creation of a global mesh network. The core of the system will be its advanced microchip technology that can be installed in any mobile or fixed device worldwide. GBT envisions this system as a low-cost, secure, private mesh network between any enabled devices, providing shared processing, advanced mobile database management/sharing and enhanced mobile features as an alternative to traditional carrier services.
OVERSOLD here..loading here
OVERSOLD here.. I am loading on this one
KPAY .031 OVERSOLD here..I am loading today
KPAY .031 OVERSOLD here..I am loading today
I am loading up to end of month
adding more today
OVERSOLD here..I am buying today .001
almost doubled from when i mentioned it 12/5
consolidation at these levels before we move higher, those who were expecting a double on this overnite disappointed i guess...hold this one for break above .35, then .40
BULLISH move today off lows
I am loading BIG all day today, below .29
Way below IPO priced at .40, OVERSOLD, I am Loading into close
up to $57M payment
Great news..to be presented on Sunday...Sunesis Pharmaceuticals Announces Data from Ongoing Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies
GlobeNewswire GlobeNewswireDecember 5, 2019
Poster to be Presented at Upcoming ASH Annual Meeting
SOUTH SAN FRANCISCO, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (SNSS) today announced data from the Company’s Phase 1b/2 clinical trial of its non-covalent BTK inhibitor vecabrutinib in adults with relapsed/refractory chronic lymphocytic leukemia (CLL) and other B-cell malignancies. The results will be presented on Sunday, December 8, from 6:00-8:00 p.m. ET in a poster session titled “CLL: Therapy, excluding Transplantation: Poster II” at the 60th American Society of Hematology (ASH) Annual Meeting in Orlando, Florida. The poster, titled “Ongoing Results of a Phase 1b/2 Dose Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton’s Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Cell Malignancies,” Abstract No. 3041, will be available at www.sunesis.com on Sunday.
The data are being disclosed in advance of the ASH meeting due to an unauthorized disclosure of the poster on social media this morning.
“The data are encouraging, with vecabrutinib showing evidence of clinical activity in high-risk patients resistant to covalent BTK inhibitors, in both wild-type and C481-mutated BTK disease,” said Dayton Misfeldt, Interim Chief Executive Officer of Sunesis. “Vecabrutinib is very well tolerated at the dose levels studied thus far, with patients now being treated in the 400 mg cohort. We are prepared for Phase 2 expansion, which will focus on BTK inhibitor-resistant CLL/SLL patients and those with prior intolerance to other BTK inhibitors.”
Data reported today were from 29 relapsed/refractory patients treated in Cohorts 1 to 5 (25 mg to 300 mg). These included 23 patients with CLL, three with Waldenstrom macroglobulinemia (WM), two with mantle cell lymphoma (MCL), and one with marginal zone lymphoma (MZL). Patients had received an average of 4 lines of prior therapy, and all had progressed on prior BTK inhibitor therapy; 61% of the CLL patients had a BTK C481 mutation.
The poster builds vecabrutinib’s profile in four key areas:
Safety: The most common treatment-emergent adverse events (TEAEs) of any grade were anemia (35%), headache (28%), and night sweats (24%). Headache and nausea (both 10%) were the two most common drug-related TEAEs. To date, no drug-related Grade 3 or Grade 4 TEAEs have been observed at dose levels higher than 50 mg.
Activity: Clinical benefit has been observed in covalent BTK inhibitor-resistant patients with poor prognostic features and in both wild-type and C481-mutated BTK disease. In the 300mg dose group (Cohort 5), stable disease was observed in 3 of 5 patients, and two remain on treatment in Cycle 5 and Cycle 6, including a wild-type BTK CLL patient with -40% change in tumor burden at first scan. In addition, one patient from Cohort 3 remains on study in Cycle 12, having been dose escalated twice from their initial dose of 100 mg to their current dose of 300 mg.
Pharmacokinetics: Vecabrutinib showed sustained exposure over the dosing interval with both exposure and median steady-state minimum blood plasma concentration (Cmin) increasing with dose. On Day 8, steady-state median Cmin values were 75 ng/mL (Cohort 1, n=3), 451 ng/mL (Cohort 2, n=10), 873 ng/mL (Cohort 3, n=4), 1124 ng/mL (Cohort 4, n=4), and 1950 ng/mL (Cohort 5, n=5).
Pharmacodynamics: Vecabrutinib’s pharmacodynamic effects (reductions in chemokines CCL3 and CCL4) increased with dose in CLL patients and indicate increased impact on BTK signaling as dose is escalated.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company developing novel targeted inhibitors for the treatment of hematologic and solid cancers. Sunesis has built an experienced drug development organization committed to improving the lives of people with cancer. The Company is focused on advancing its novel kinase inhibitor pipeline, with an emphasis on its oral non-covalent BTK inhibitor vecabrutinib. Vecabrutinib is currently being evaluated in a Phase 1b/2 study in adults with chronic lymphocytic leukemia and other B-cell malignancies that have progressed after prior therapies.
For additional information on Sunesis, please visit www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc
OVERSOLD here, I am buying today at .045
opening position today..oversold here
AITX .0014 OVERSOLD..news this am..Artificial Intelligence Technology Solutions Enters Energy Sector with Oil and Gas as Another Vertical
GLOBENEWSWIRE 9:00 AM ET 6/19/2019
RENO, NV, June 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Artificial Intelligence Technology Solutions, Inc.(AITX), (AITX: OTCPK) is pleased to announce that Robotic Assistance Devices (RAD), its wholly owned subsidiary, has entered into a pilot for a SCOT unit with a Fortune 500 oil refinery client.
“We are pleased to be adding a new vertical to our growing client base,” said Steve Reinharz, President and CEO of Robotic Assistance Devices. “The size and scope of the energy industry presents a significant opportunity for us moving forward to add new clients in this vertical,”
The pilot if for 30 days after which if satisfied, the agreement will convert to a 12 month commercial agreement.
RAD is in discussions with numerous other potential clients and expects more orders in the near future.
The company may post important information about its subsidiary RAD on its website at www.Robotic AssistanceDevices.com and through tweets from RAD President and CEO Steve Reinharz
AITX .0014 OVERSOLD..news this am..Artificial Intelligence Technology Solutions Enters Energy Sector with Oil and Gas as Another Vertical
GLOBENEWSWIRE 9:00 AM ET 6/19/2019
RENO, NV, June 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Artificial Intelligence Technology Solutions, Inc.(AITX), (AITX: OTCPK) is pleased to announce that Robotic Assistance Devices (RAD), its wholly owned subsidiary, has entered into a pilot for a SCOT unit with a Fortune 500 oil refinery client.
“We are pleased to be adding a new vertical to our growing client base,” said Steve Reinharz, President and CEO of Robotic Assistance Devices. “The size and scope of the energy industry presents a significant opportunity for us moving forward to add new clients in this vertical,”
The pilot if for 30 days after which if satisfied, the agreement will convert to a 12 month commercial agreement.
RAD is in discussions with numerous other potential clients and expects more orders in the near future.
The company may post important information about its subsidiary RAD on its website at www.Robotic AssistanceDevices.com and through tweets from RAD President and CEO Steve Reinharz
GXXM oversold .0003 NEWS! Dallas, Texas, June 17, 2019 (GLOBE NEWSWIRE) -- GEX Management Inc(GXXM) , a Dallas based management and professional services company, today announced its continued strategic initiatives focused on building a premium staffing and consulting business line complementary to its organic and inorganic growth initiatives.
Sri Vanamali, the Executive Director of GEX Management Inc.(GXXM) said, “As mentioned in our past announcements, GEX is in the process of restructuring and reorganizing its operational and capital infrastructure in a way that is primed to help the company build a solid foundation for growth in 2019 and beyond. “ As part of this renewed strategy, GEX Management(GXXM) has set strategic goals to expand further into areas of higher margin and growth business categories particularly in the space of IT and Management Consulting as well as identify synergistic opportunities in healthcare sector to deliver significant cost rationalization, benefits and integrated staffing solutions to clients and customers alike.
In alignment with this strategy, GEX Management(GXXM) has partnered as a Preferred IT Solutions Supplier to one of the premier Managed Service Providers (MSPs) to Fortune 100 Companies in the Enterprise Technology Consulting and Staffing solutions space. This has resulted in a significant business development pipeline that is projected to generate solid revenue and growth opportunities going forward. Additionally, GEX executed a strategic staffing agreement with a leading Ohio based Healthcare group to deliver staffing, HR management, payroll processing and benefit administration services to the client’s healthcare and clinical practice centers in the mid-west region. Management expects these and other growth opportunities to help the firm achieve strong revenue growth and help move towards higher profitability profiles then in the past by targeting higher margin, lower cost business models and relying on less expensive debt instruments to help reduce the burden across the firm’s capital structure while maximizing efficient use of operating capital.
“The management is committed to continue focusing on improving the balance sheet in the near term while also identifying sustainable long-term growth opportunities through strategic partnerships with established MSPs. Based on efforts related to these partnerships, we have already won 2 new consulting contracts - one with a large Pennsylvania based Investment Management firm and another with a Florida based, global technology firm focused on the travel industry; we expect more contracts and placements to follow over the coming months based on our multi-tiered sales and recruiting strategy as we continue to place quality resources towards these long term opportunities”, said Sri Vanamali.
“These organic growth initiatives are expected to bear fruit over the next few months and begin gaining traction starting Q4 2019 and beyond, as we place more consultants and build towards the strength of our strategic relationships. Additionally, our Corporate Strategy team has developed a structured process to identify, review and close potential synergistic acquisition targets that will be complementary to the GEX Management Business Ecosystem. I am very excited to work with our investors, business partners and service providers to continue the positive momentum despite past challenges and am confident of GEX achieving great long term success with this renewed strategy. We will make further announcements to our investors and shareholders as we make progress with these initiatives”.
About GEX Management(GXXM)
GEX Management, Inc. (GXXM) Is a Professional Services Company providing consulting, staffing and comprehensive managed service solutions to clients in a variety of industries. GEX Management(GXXM) services include IT and Strategy Consulting, Staffing, HR, Payroll, Risk & Compliance, and Executive Consulting, and provides progressive and complete solutions for employee management and operational needs
GXXM 738m bid .0001 5m ask .0002
GXXM 738m bid .0001 5m ask .0002
GXXM .0002 OVERSOLD..I will add .0002 once it starts to thin on L2 726m on Bid 32m on ask
I will add .0002 once it starts to thin on L2 726m on Bid 32m on ask
ALYI .012 OVERSOLD..I am loading today
ALYI .012 OVERSOLD..I am loading today
agreed, big supply on bid, gradual acc on thin ask
LOL Mr clean said it correctly on BRKK "It’s actually not that hard. Don’t chase anything. Buy the stock when it has the most people like you. Complaining. Sell it when everyone is excited about it going to .50
Learn that and you’ll stop complaining so much"
LOL..still good job on picking the bottom on HTTI..seems like you know what you are doing...
Large increase in vol today...could retrace recent highs next week
GNBT 1.13 OVERSOLD..BIG news just out!!...Generex Biotechnology Announces Share Dividend & Strategic Plans
GlobeNewswire•May 31, 2019
MIRAMAR, Fla., May 31, 2019 (GLOBE NEWSWIRE) -- Generex Biotechnology is pleased to announce that the company plans to declare a 1:1 stock dividend, contingent upon the successful up listing to NASDAQ, to complete the strategic reorganization from a pure development company to a an end-to-end solutions provider for physicians and patients.
Joseph Moscato, CEO of Generex stated, “On June 20th, Generex plans to declare a 1 for 1 dividend for shareholders of record with certain conditions, noting that verbal commitments have been given that the dividend will be waived by all insiders and other major equity holders not in the public float. Once that is formalized, this dividend will be the last dividend from the company in conjunction with its completion of its current overall three-stage development plan.
As promised, when the shareholders approved the reverse stock split in 2017, allowing us to clean up the company’s security structure, I followed through on our commitment to give back to our shareholders for allowing us to execute on our plan, creating significant value in the company. When we have achieved certain milestones, we have made a point to give back to our valuable shareholders in the form of dividends, including the 20:1 dividend in Generex shares and the 1:4 dividend in NuGenerex Immuno-Oncology. This final dividend in this cycle is a symbol of our success and thanks, and our continued commitment to give back to our shareholders.”
Over the last three months, Generex has made significant strides in executing on its strategic plans, and intends to file an S1 registration statement with the SEC in the coming weeks. The company’s subsidiary Olaregen launched Excellagen, which is FDA cleared for wound management, selling out the first commercial lot in less than a month. The company is reorganizing its MSO model with expanded controls and compliance standards and expanding into new geographic territories. In the last few weeks, Generex has finalized terms for the acquisitions of Pantheon Medical and Medicsource Partners, which are expected to close shortly. Generex is also expanding the NuGenerex family of companies with the formation of NuGenerex Chronic Care Solutions that will provide ancillary health services for a multi-clinic endocrinology practice that serves a large population of patients with diabetes and metabolic disorders.
Mr. Moscato added, “The final future piece of our corporate vision is the establishment of an HMO, NuGenerex Health, in partnership with Dr. Kiran Patel, who most recently sold his prior HMO, Freedom Health to Anthem for $1.8 billion. This exciting opportunity with Dr. Patel demonstrates our commitment to build a new kind of healthcare company that develops and delivers innovative new products like Excellagen and specialty health services like NuGenerex Chronic Care Solutions to provide end-to-end solutions for physicians and patients in our HMO network. Dr. Patel has done seven successful HMOs and I am honored to have the preeminent leader in the HMO sector and utilize his world class experience in creating NuGenerex Health Services.”
The company will provide complete details of the dividend on Thursday June 20th as well as declaration, pay date and ex-date.
About Generex Biotechnology Corp.
Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.
In addition to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital. Recent acquisitions include a management services organization, a network of pharmacies, clinical laboratory, and medical device companies with new and approved products.
Our newly formed, wholly-owned subsidiary, NuGenerex Distribution Solutions (NDS), integrates our MSO network with a pharmacy network, clinical diagnostic lab, durable medical equipment company (DME-IQ) and dedicated call center
div news out 9.45 am halted
GNBT dividend news ! halted...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148498568